Please login to the form below

Not currently logged in
Email:
Password:

PhRMA attacks Indian courtís Glivec patent ruling

The Pharmaceutical Research and Manufacturers of America attacks an Indian court ruling to deny patent protection for Novartis' cancer drug, Glivec

According to US media reports, the Pharmaceutical Research and Manufacturers of America (PhRMA), a representative body of US drug firms, has attacked an Indian court ruling to deny patent protection for Novartis' cancer drug, Glivec (imatinib).

PhRMA said the decision would weaken incentives for new innovations in India. Members of the association have invested approximately USD 43bn in 2006 to aid the discovery and development of new medicines. Industry-wide research and investment reached a record USD 55.2bn in 2006.

PhRMA's CEO Billy Tauzin said: "We are disappointed the Indian court dismissed the challenge to Section 3 (d) of India's 2005 Patent Law. We are concerned that the result is likely to be reduced patient access to better medicines discovered through incremental innovation."

"Breakthrough innovations are important but rare in medical research. Most medical advances like in other technological fields happen by incremental innovation; that is, innovation that builds on previous inventions," added Tauzin.

14th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...